Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated darbepoetin beta
- Development stage
- Phase 3
- Lead developer
- Biocad
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Pegylated darbepoetin beta is a **long-acting erythropoiesis-stimulating agent (ESA)** that is chemically a pegylated (polyethylene glycol-conjugated) form of darbepoetin beta—a recombinant protein analog of human erythropoietin. Pegylation extends the half-life and stability of the molecule, allowing for less frequent dosing. Like other ESAs, it **stimulates erythropoiesis** by binding to the erythropoietin (EPO) receptor on erythroid progenitor cells in the bone marrow, promoting red blood cell formation. This form was developed to treat anemia associated with **chronic kidney disease** and other causes. Pegylated darbepoetin beta was developed by Biocad Medical and is under clinical development, with the highest R&D phase being Phase 3 for anemia and chronic kidney failure[5].
- Other names
- pegylated darbepoetin betapegylated darbepoetin
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on pegylated darbepoetin beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated darbepoetin beta.